辉瑞与METSERA达成合并协议修正案

Core Viewpoint - Pfizer has reached a revised merger agreement with METSERA, with the board of METSERA reaffirming its support for the merger [1] Group 1: Merger Details - Pfizer will acquire METSERA for $65.60 per share in cash, plus a maximum of $20.65 in contingent value rights (CVR) [1] - The revised transaction values METSERA at up to $86.25 per share [1] Group 2: Shareholder Approval - METSERA has unanimously recommended that its shareholders approve the revised merger agreement with Pfizer [1]